Exicure closed at $0.94 on Nov 4, down 7.22%, within 0.2% of its 52-week closing low. Volume of 10.7K shares was 0.16× its 20-day average (below normal).
Split-adjusted performance: -13.2% over one month, -72.4% over six months, -77.7% over one year.
Short interest was 42.9K shares at the Oct 15 settlement, up 14.2% from the prior report (1.1% of float, 1.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| XCURExicure | $0.9371 | −7.22% | −72.4% | — | — | — | $6.1M | |
| CNSPCNS Pharmaceuticals | $4.06 | −10.77% | −41.2% | — | — | — | $5.9M | Compare |
| APREAprea Therapeutics | $0.5141 | −0.17% | −38.3% | −100.0% | — | — | $6.5M | Compare |
| ENVBEnveric Biosciences | $1.46 | −2.67% | −54.1% | — | — | — | $6.5M | Compare |
| LGVNLongeveron | $1.79 | +0.56% | −79.5% | −9.2% | −2116.0% | — | $5.7M | Compare |
| NAIINatural Alternatives International | $1.07 | +0.94% | −60.7% | +1.9% | −39.2% | — | $6.7M | Compare |
| SCNXScienture Holdings | $3.41 | −1.16% | −65.1% | — | −821.3% | — | $5.6M | Compare |
| ACXPAcurx Pharmaceuticals | $1.02 | 0.00% | −51.2% | — | — | — | $5.6M | Compare |
| FBLGFibroBiologics | $0.9735 | −1.67% | −24.5% | — | — | — | $6.9M | Compare |
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
